SCHEMBL7224015

SCHEMBL7224015

CN1CC(c2ccc(C(=O)NCCc3ccc4[nH]cc(C(=N)N)c4c3)cc2)CN(C)C1=O

nearest known ligand 0.44

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.44
LMNA P02545 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HAT1 O14929 1/20 0.39
EP300 Q09472 1/20 0.39
SNCA P37840 7/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 2/20 0.38
ACHE P22303 1/20 0.38
GAA P10253 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7232847 0.87 HAT1 (0.52) TRPV1LMNAL3MBTL1HAT1EP300
SCHEMBL7222939 0.85 TRPV1 (0.43) TRPV1LMNAL3MBTL1SNCAKMT2A
SCHEMBL7231259 0.84 TRPV1 (0.48) TRPV1LMNAL3MBTL1HAT1EP300
SCHEMBL7224364 0.84 HAT1 (0.47) TRPV1LMNAL3MBTL1HAT1EP300
SCHEMBL7222007 0.84 SNCA (0.45) TRPV1SNCAKMT2APOLBACHE
SCHEMBL7222496 0.84 TRPV1 (0.46) TRPV1LMNAL3MBTL1HAT1EP300
SCHEMBL7231452 0.83 TRPV1 (0.46) TRPV1LMNAL3MBTL1HAT1EP300
SCHEMBL7222215 0.82 TRPV1 (0.47) TRPV1LMNAL3MBTL1HAT1EP300
SCHEMBL7233757 0.82 TRPV1 (0.45) TRPV1LMNAL3MBTL1SNCAKMT2A
SCHEMBL7234303 0.80 ESRRG (0.54) TRPV1LMNAL3MBTL1SNCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030153604-A1 Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds AVENTIS PHARMACEUTICALS INC. 2003-08-14 US claimed
US-6541505-B1 Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. AVENTIS PHARMACEUTICALS INC. 2003-04-01 US claimed
EP-1140901-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2001-10-10 EP claimed
WO-2000039087-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-07-06 WO claimed
US-20030153604-A1 Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds AVENTIS PHARMACEUTICALS INC. 2003-08-14 US disclosed
US-6541505-B1 Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. AVENTIS PHARMACEUTICALS INC. 2003-04-01 US disclosed
EP-1140901-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2001-10-10 EP disclosed
WO-2000039087-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153604-A1 Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds SERPINC1, F2, F11 TRPV1 4561/4885LMNA 493/4885L3MBTL1 2863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.